<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00688428</url>
  </required_header>
  <id_info>
    <org_study_id>D961FC00002</org_study_id>
    <nct_id>NCT00688428</nct_id>
  </id_info>
  <brief_title>Study Comparing a Fixed-Dose Capsule of Esomeprazole 40mg and LDA 325mg With Free Combination</brief_title>
  <official_title>A Phase I, Open-Label, Randomized, Single-Center, 2-Stage Group Sequential Design, 2-Way Crossover Bioequivalence Study Comparing a Fixed-Dose Combination Capsule of Esomeprazole 40mg and Low-Dose Acetylsalicylic Acid (ASA) 325mg With a Free Combination of Esomeprazole Capsule 40mg and Low-Dose ASA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test if fixed dose esomeprazole and ASA capsule is
      pharmaceutically equal to a free combination of esomeprazole capsule and ASA tablet
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Samples for measurement of esomeprazole, ASA, and SA concentrations</measure>
    <time_frame>Day 1 of each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting blood samples for determination of clinical chemistry and hematology parameters</measure>
    <time_frame>screening and follow up visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine samples for urinalysis parameters</measure>
    <time_frame>screening, Period 1, and follow-up visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Ulcers</condition>
  <condition>Upper GI Symptoms</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>combination capsule of Esomeprazole 40mg + ASA 325mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole 40 mg capsule and ASA 325 mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40mg/ASA 325mg</intervention_name>
    <description>combination capsule, administered as a single oral dose</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Nexium/Bayer Aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>40mg capsule, administered as a single dose</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASA</intervention_name>
    <description>325mg tablet, administered as a single oral dose</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Bayer aspirin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index of 19-29kg/m2, inclusive

          -  Weight of 50-95kg, inclusive

          -  Clinically normal physical findings and laboratory values including hepatitis B,
             hepatitis C, and HIV, as judged by the Investigator

        Exclusion Criteria:

          -  Significant clinical illness within the 2 weeks preceding the first dose of
             investigational products, as judged by the Investigator

          -  History of mental, cardiac, renal, hepatitis, neurological, or significant
             gastrointestinal disease, as judged by the Investigator

          -  Condition which could modify the absorption of the investigational products, as judged
             by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JÃ¶rgen Naesdal, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Billings ., D.O</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biokinetics Clinical Applications</affiliation>
  </overall_official>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>June 2, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2008</study_first_posted>
  <last_update_submitted>March 11, 2009</last_update_submitted>
  <last_update_submitted_qc>March 11, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2009</last_update_posted>
  <responsible_party>
    <name_title>Tore Lind, MD, Medical Science Director NEXIUM and GI Established Brands</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>esomeprazole</keyword>
  <keyword>upper gi symptoms</keyword>
  <keyword>low dose Aspirin treatment</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

